Highlights: • Incannex has received approval from Bellberry Human Research Ethics Committee (‘HREC’) to commence the bioavailability/bioequivalence (‘BA/BE’) clinical trial… Read more
Incannex has changed its registered office.
Event: H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference Date: June 26, 2023
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical… Read more
Highlights: • Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board. o Dr. Bill Richards is among the world’s… Read more
The Company is extremely pleased to announce that the Offer has now closed and has been heavily oversubscribed. The issue… Read more
Psychennex Pty Ltd Psychedelic-assisted psychotherapy offers the hope of sustained improvement to the significant proportion of people for whom traditional… Read more
Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a medicinal cannabinoid and psychedelic pharmaceutical development company, is… Read more
For a non-renounceable pro rata offer of 1 option to acquire a fully paid ordinary share in the Company (Loyalty… Read more